Jonathan D Cogen1,2, Frankline M Onchiri2, Nicole Mayer Hamblett1,2,3, Ronald L Gibson1,2, Wayne J Morgan4, Margaret Rosenfeld1,2. 1. Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA. 2. Seattle Children's Research Institute, Seattle, Washington, USA. 3. Department of Biostatistics, University of Washington School of Medicine, Seattle, Washington, USA. 4. Department of Pediatrics, The University of Arizona, Tucson, Arizona, USA.
Abstract
BACKGROUND: While Pseudomonas aeruginosa (Pa) eradication regimens have contributed to a decline in Pa prevalence in people with cystic fibrosis (CF), this antibiotic exposure might increase the risk of acquisition of drug-resistant organisms. This study evaluated the association between antipseudomonal antibiotic exposure intensity and acquisition risk of drug-resistant organisms among children with CF and new Pa infection. METHODS: We utilized data from the Early Pseudomonas Infection Control Clinical Trial (EPIC CT), a randomized controlled trial comparing Pa eradication strategies in children with CF and new Pa. The exposure was the number of weeks of oral or inhaled antipseudomonal antibiotics or ever versus never treatment with intravenous antipseudomonal antibiotics during the 18 months of EPIC CT participation. Primary outcomes were risks of acquisition of several respiratory organisms during 5 years of follow-up after EPIC CT estimated using Cox proportional hazards models separately for each specific organism. RESULTS: Among 249 participants, there was no increased acquisition risk of any organism associated with greater inhaled antibiotic exposure. With each additional week of oral antibiotics, there was an increased hazard of Achromobacter xylosoxidans acquisition (HR, 1.24; 95% CI: 1.02-1.50; P = .03). Treatment with intravenous antibiotics was associated with an increased hazard of acquisition of multidrug-resistant Pa (HR, 2.47; 95% CI: 1.28-4.78; P = .01) and MRSA (HR, 1.57; 95% CI: 1.03-2.40; P = .04). CONCLUSIONS: Results from this study illustrate the importance of making careful antibiotic choices to balance the benefits of antibiotics in people with CF while minimizing risk of acquisition of drug-resistant organisms.
BACKGROUND: While Pseudomonas aeruginosa (Pa) eradication regimens have contributed to a decline in Pa prevalence in people with cystic fibrosis (CF), this antibiotic exposure might increase the risk of acquisition of drug-resistant organisms. This study evaluated the association between antipseudomonal antibiotic exposure intensity and acquisition risk of drug-resistant organisms among children with CF and new Pa infection. METHODS: We utilized data from the Early Pseudomonas Infection Control Clinical Trial (EPIC CT), a randomized controlled trial comparing Pa eradication strategies in children with CF and new Pa. The exposure was the number of weeks of oral or inhaled antipseudomonal antibiotics or ever versus never treatment with intravenous antipseudomonal antibiotics during the 18 months of EPIC CT participation. Primary outcomes were risks of acquisition of several respiratory organisms during 5 years of follow-up after EPIC CT estimated using Cox proportional hazards models separately for each specific organism. RESULTS: Among 249 participants, there was no increased acquisition risk of any organism associated with greater inhaled antibiotic exposure. With each additional week of oral antibiotics, there was an increased hazard of Achromobacter xylosoxidans acquisition (HR, 1.24; 95% CI: 1.02-1.50; P = .03). Treatment with intravenous antibiotics was associated with an increased hazard of acquisition of multidrug-resistant Pa (HR, 2.47; 95% CI: 1.28-4.78; P = .01) and MRSA (HR, 1.57; 95% CI: 1.03-2.40; P = .04). CONCLUSIONS: Results from this study illustrate the importance of making careful antibiotic choices to balance the benefits of antibiotics in people with CF while minimizing risk of acquisition of drug-resistant organisms.
Authors: Ana C Blanchard; Eric Horton; Sanja Stanojevic; Louise Taylor; Valerie Waters; Felix Ratjen Journal: J Cyst Fibros Date: 2017-02-09 Impact factor: 5.482
Authors: Sabariah Noor Harun; Nicholas H G Holford; Keith Grimwood; Claire E Wainwright; Stefanie Hennig Journal: Thorax Date: 2019-06-15 Impact factor: 9.139
Authors: M Rosenfeld; J Emerson; F Accurso; D Armstrong; R Castile; K Grimwood; P Hiatt; K McCoy; S McNamara; B Ramsey; J Wagener Journal: Pediatr Pulmonol Date: 1999-11
Authors: Don B Sanders; Rachel C L Bittner; Margaret Rosenfeld; Lucas R Hoffman; Gregory J Redding; Christopher H Goss Journal: Am J Respir Crit Care Med Date: 2010-05-12 Impact factor: 21.405
Authors: Miriam M Treggiari; George Retsch-Bogart; Nicole Mayer-Hamblett; Umer Khan; Michal Kulich; Richard Kronmal; Judy Williams; Peter Hiatt; Ronald L Gibson; Terry Spencer; David Orenstein; Barbara A Chatfield; Deborah K Froh; Jane L Burns; Margaret Rosenfeld; Bonnie W Ramsey Journal: Arch Pediatr Adolesc Med Date: 2011-09
Authors: Nicole Mayer-Hamblett; George Retsch-Bogart; Margaret Kloster; Frank Accurso; Margaret Rosenfeld; Gary Albers; Philip Black; Perry Brown; AnneMarie Cairns; Stephanie D Davis; Gavin R Graff; Gwendolyn S Kerby; David Orenstein; Rachael Buckingham; Bonnie W Ramsey Journal: Am J Respir Crit Care Med Date: 2018-11-01 Impact factor: 30.528